The concentration of high-sensitivity troponin I, galectin-3 and NT-proBNP substantially increase after a 60-km ultramarathon

2014 ◽  
Vol 52 (2) ◽  
Author(s):  
Gian Luca Salvagno ◽  
Federico Schena ◽  
Matteo Gelati ◽  
Elisa Danese ◽  
Gianfranco Cervellin ◽  
...  
Keyword(s):  
Endurance Exercise ◽  
High Intensity ◽  
Cardiac Fibrosis ◽  
Troponin I ◽  
High Sensitivity ◽  
High Sensitivity Troponin ◽  
Diagnostic Threshold ◽  
Galectin 3 ◽  
Study Population ◽  
Amount Of Knowledge

AbstractThe leading mechanisms responsible for the most prevalent and serious cardiac injuries include myocardiocyte stretch, myocardiocyte necrosis and cardiac fibrosis, which can now be reliably mirrored by measurement of natriuretic peptides, cardiospecific troponins and galectin-3, respectively. Although a large amount of knowledge has been gathered about the behavior and clinical significance of these biomarkers in patients with cardiac disorders, less information is available on their biology in paraphysiological conditions, including high-intensity endurance exercise.The study population consisted of 18 trained athletes, who performed a 60-km ultramarathon run. Blood was collected before the run (i.e., “baseline”) and immediately after the end of the ultramarathon (“post-marathon”) for measurement of serum high-sensitivity troponin I (TnI), NT-proBNP and galectin-3.The concentration of all biomarkers measured in the post-marathon samples was remarkably increased as compared with the values obtained on baseline specimens. In particular, the median increase was 3.3 for TnI, 3.5 for NT-proBNP and 2.4 for galectin-3, respectively. The frequency of values exceeding the diagnostic threshold did not differ at baseline and after the ultramarathon for TnI (6% vs. 25%; p=0.15), instead was significantly increased for NT-proBNP (0% vs. 28%; p=0.016) and galectin-3 (0% vs. 67%; p<0.001). No significant correlation was found among the increase of any of the three biomarkers.The results of this study demonstrate that high-intensity endurance exercise is associated with biochemical abnormalities that may reflect adverse consequences on cardiac structure and biology.

High-sensitivity Troponin I Predicts Galectin-3 in Chronic Kidney Disease Patients

2020 ◽  
Vol 52 (3) ◽  
pp. 533-540
Author(s):  
Gek Cher Chan ◽  
Peh Joo Ho ◽  
Jialiang Li ◽  
Evan Jon Choon Lee ◽  
Horng Ruey Chua ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Troponin I ◽  
High Sensitivity ◽  
High Sensitivity Troponin ◽  
Galectin 3

scholarly journals Short- and Long-term Biologic Variability of Galectin-3 and Other Cardiac Biomarkers in Patients with Stable Heart Failure and Healthy Adults

2016 ◽  
Vol 62 (2) ◽  
pp. 360-366 ◽  
Author(s):  
Emily I Schindler ◽  
Jeffrey J Szymanski ◽  
Karl G Hock ◽  
Edward M Geltman ◽  
Mitchell G Scott
Keyword(s):  
Heart Failure ◽  
Troponin I ◽  
Prognostic Biomarker ◽  
High Sensitivity ◽  
Cardiac Biomarkers ◽  
Healthy Individuals ◽  
Short Term ◽  
Galectin 3 ◽  
Short And Long Term

Abstract BACKGROUND Galectin-3 (Gal-3) has been suggested as a prognostic biomarker in heart failure (HF) patients that may better reflect disease progression than traditional markers, including B-type natriuretic peptide (BNP) and cardiac troponins. To fully establish the utility of any biomarker in HF, its biologic variability must be characterized. METHODS To assess biologic variability, 59 patients were prospectively recruited, including 23 male and 16 female patients with stable HF and 10 male and 10 female healthy individuals. Gal-3, BNP, and high-sensitivity cardiac troponin I (hs-cTnI) were assayed at 5 time points within a 3-week period to assess short-term biologic variability. Long-term (3-month) biologic variability was assessed with samples collected at enrollment and after 4, 8, and 12 weeks. RESULTS Among healthy individuals, mean short-term biologic variability, expressed as intraindividual CV (CVI), was 4.5% for Gal-3, 29.0% for BNP, and 14.5% for hs-cTnI; long-term biologic variability was 5.5% for Gal-3, 34.7% for BNP, and 14.7% for hs-cTnI. In stable HF patients, mean short-term biologic variability was 7.1% for Gal-3, 22.5% for BNP, and 8.5% for hs-cTnI, and mean long-term biologic variability was 7.7% for Gal-3, 27.6% for BNP, and 9.6% for hs-cTnI. CONCLUSIONS The finding that Gal-3 has minimal intraindividual biological variability adds to its potential as a useful biomarker in HF patients.

scholarly journals Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors

2021 ◽  
Vol 3 (1) ◽  
pp. 137-139
Author(s):  
Sarah Waliany ◽  
Joel W. Neal ◽  
Sunil Reddy ◽  
Heather Wakelee ◽  
Sumit A. Shah ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Troponin I ◽  
Checkpoint Inhibitors ◽  
High Sensitivity ◽  
High Sensitivity Troponin

First description of elevated high-sensitivity troponin I for pufferfish poisoning: a case report

2021 ◽  
Author(s):  
Akkan Avci ◽  
Hayri Cınar ◽  
Onder Yesiloglu ◽  
Begum Seyda Avci ◽  
Hasan Yesilagac ◽  
...  
Keyword(s):  
Case Report ◽  
Troponin I ◽  
High Sensitivity ◽  
High Sensitivity Troponin

scholarly journals Myocardial injury after pulmonary vein isolation: fire versus ice

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
A R Morgado Gomes ◽  
N S C Antonio ◽  
S Silva ◽  
M Madeira ◽  
P Sousa ◽  
...  
Keyword(s):  
Pulmonary Vein ◽  
Pulmonary Vein Isolation ◽  
Troponin I ◽  
Surrogate Marker ◽  
High Sensitivity ◽  
Cryoballoon Ablation ◽  
Single Shot ◽  
High Sensitivity Troponin ◽  
Ablation Index ◽  
Significant Difference

Abstract Introduction The cornerstone of atrial fibrillation (AF) catheter ablation is pulmonary vein isolation (PVI), either using point-by-point radiofrequency ablation (RF) or single-shot ablation devices, such as cryoballoon ablation (CB). However, achieving permanent transmural lesions is difficult and pulmonary vein (PV) reconnection is common. Elevation of high-sensitivity Troponin I (hsTnI) may be used as a surrogate marker for transmural lesions. Still, data regarding the comparison of hsTnI increase after PVI with RF or cryo-energy is controversial. Purpose The aim of this study is to compare the magnitude of hsTnI elevation after PVI with CB versus RF using ablation index guidance. Methods Prospective study of 60 patients admitted for first ablation procedure of paroxysmal or persistent AF in a single tertiary Cardiology Department. Thirty patients were submitted to PVI using CB and 30 patients were submitted to RF, using CARTO® mapping system and ablation index guidance. Patients with atrial flutter were excluded. Baseline characteristics were compared between groups, as well as hsTnI before and after the procedure. Results Mean age was 57.9±12.3 years old, 62% of patients were male and 77% had paroxysmal AF. There were no significant differences between groups regarding gender, age, prevalence of hypertension, dyslipidaemia, diabetes, obesity or AF type. There was also no significant difference in electrical cardioversion need during the procedure. HsTnI median value before ablation was 1.90±1.98 ng/dL. Postprocedural hsTnI was significantly higher in CB-group (6562.7±4756.2 ng/dL versus 1564.3±830.7 ng/dL in RF-group; P=0.001). Regarding periprocedural complications, there was only one case of mild pericardial effusion in RF-group associated with postablation hsTnI of 1180.0 ng/dL. Conclusions High-sensitivity Troponin I was significantly elevated after PVI, irrespective of the ablation technique. In CB-group, hsTnI elevation was significantly higher than in RF-group. This disparity may reflect more extensive lesions with cryoablation, without compromising safety. Longterm studies are needed to understand whether this hsTnI elevation is predictive of a lower AF recurrence rate. FUNDunding Acknowledgement Type of funding sources: None.

Sign in / Sign up

Export Citation Format

Share Document